Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.654
Abstract: Daprodustat, a small‐molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia‐inducible factor (HIF), leading to increased transcription of HIF‐responsive genes. This randomized, placebo‐controlled study evaluated the safety, tolerability, and pharmacokinetics of a topical formulation of… read more here.
Keywords: daprodustat; safety tolerability; safety; healthy volunteers ... See more keywords
Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "International Urology and Nephrology"
DOI: 10.1007/s11255-018-1940-8
Abstract: BackgroundThe efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy… read more here.
Keywords: daprodustat; patients chronic; kidney disease; chronic kidney ... See more keywords
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab085.0022
Abstract: The Anemia Study in Chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor (PHI) Daprodustat-Non-Dialysis (ASCEND-ND; NCT02876835) trial is evaluating the efficacy and safety of daprodustat when compared with darbepoetin alfa in CKD… read more here.
Keywords: darbepoetin alfa; study; daprodustat; baseline characteristics ... See more keywords
Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13839
Abstract: Daprodustat is an approved treatment for anemia of chronic kidney disease (CKD) in Japan. read more here.
Keywords: kidney disease; daprodustat; chronic kidney; anemia chronic ... See more keywords
Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.746265
Abstract: Introduction: Daprodustat, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at investigating its efficacy and safety on the treatment of patients with chronic kidney… read more here.
Keywords: safety; ckd patients; analysis; daprodustat ... See more keywords